About Us

Headquartered in Shanghai, China, Vcell healthcare is a biotech company focused on the development, manufacturing and commercialization of advanced mAb biosimilars in China, with a commitment of bringing affordable world-class biological therapeutics to Chinese patients. It is a joint venture established in 2019 by Celltrion, a leading biopharmaceutical company which has developed world's first mAb biosimilar that has received US FDA /EMA approval, and Nan Fung Group, a renowned conglomerate based in Hong Kong. Vcell has in-licensed several US FDA and EMA approved biosimilar products from Celltrion, including Remsima®,Truxima® and Herzuma®, all have been proven their efficacy and safety through multiple global clinical trials.

Vcell has an international management team and pursues the "people-oriented" company culture. We respect diversity and encourage each employee to fully fulfill their potential and achieve career advancement along with the rapid expansion of our company.

At Vcell, we strive to make world-class biological therapeutics affordable and accessible to every Chinese patient. If you share the same passion and dream, please join us to make a difference and shape China's biosimilar industry together.
Contact Us
Suite1202B, 12F, Tower 2, 1239 Century Avenue, Century Metropolis, Pudong District, Shanghai, PRC
Email: dingsai@vcellhealthcare.com /Career: HR@vcellhealthcare.com/Patient Recruitment: clinicaltrial@vcellhealthcare.com
©2019 Vcell Healthcare Limited 沪ICP备19024936号
Power By : A+T